{"id":7733,"date":"2025-07-01T21:31:15","date_gmt":"2025-07-01T13:31:15","guid":{"rendered":"https:\/\/allcancer.com\/cancer\/acute-myeloid-leukemia-aml\/"},"modified":"2025-07-09T23:39:30","modified_gmt":"2025-07-09T15:39:30","slug":"%e6%80%a5%e6%80%a7%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85","status":"publish","type":"cancer_type","link":"https:\/\/allcancer.com\/hk\/%e7%99%8c%e7%97%87\/%e6%80%a5%e6%80%a7%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85\/","title":{"rendered":"\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML)"},"content":{"rendered":"

\u4ec0\u9ebc\u662f \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML)<\/strong>?<\/h2>\n

\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u662f\u4e00\u7a2e\u767c\u5c55\u8fc5\u901f\u7684\u8840\u6db2\u548c\u9aa8\u9ad3\u764c\u75c7\uff0c\u7279\u5fb5\u662f\u672a\u6210\u719f\u7684\u9ad3\u7d30\u80de\u904e\u5ea6\u751f\u9577\u3002\u9019\u4e9b\u7570\u5e38\u7d30\u80de\u6703\u7834\u58de\u5065\u5eb7\u8840\u7d30\u80de\u7684\u6b63\u5e38\u88fd\u9020\u3002\u65b0\u8208\u7684\u6cbb\u7642\u65b9\u6cd5\u548c\u5c0d\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u751f\u7269\u5b78\u7684\u66f4\u6df1\u5165\u77ad\u89e3\u662f\u975e\u5e38\u91cd\u8981\u7684\uff0c\u5c24\u5176\u662f\u8003\u616e\u5230\u5176\u4fb5\u7565\u6027\u4ee5\u53ca\u5c0d\u75c5\u60a3\u53ca\u5176\u5bb6\u4eba\u6240\u9020\u6210\u7684\u91cd\u5927\u60c5\u7dd2\u548c\u8eab\u9ad4\u8ca0\u64d4\u3002<\/p>\n

\u5f9e\u751f\u7269\u5b78\u7684\u89d2\u5ea6\u4f86\u770b\uff0c\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u6d89\u53ca\u9ad3\u7cfb\u7956\u7d30\u80de\u7684\u7a81\u8b8a\uff0c\u800c\u9ad3\u7cfb\u7956\u7d30\u80de\u662f\u7522\u751f\u6210\u719f\u7d05\u8840\u7403\u3001\u767d\u8840\u7403\u548c\u8840\u5c0f\u677f\u7684\u5fc5\u8981\u7d30\u80de\u3002\u767d\u8840\u75c5\u7d30\u80de\u5feb\u901f\u3001\u7121\u6cd5\u63a7\u5236\u7684\u589e\u6b96\u6703\u8d85\u8d8a\u6b63\u5e38\u7684\u9020\u8840\u904e\u7a0b\uff0c\u5c0e\u81f4\u56b4\u91cd\u7684\u4f75\u767c\u75c7\uff0c\u5982\u8ca7\u8840\u3001\u6613\u611f\u67d3\u53ca\u51fa\u8840\u4e8b\u4ef6\u3002<\/p>\n

\u6c83\u4f2f\u683c\u6548\u61c9\u8207\u6025\u6027\u9ad3\u7d30\u80de\u4ee3\u8b1d<\/h3>\n

\u764c\u7d30\u80de\uff08\u5305\u62ec\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5 (AML) \u7d30\u80de\uff09\u6703\u51fa\u73fe\u4e00\u7a2e\u7279\u6b8a\u7684\u65b0\u9673\u4ee3\u8b1d\u9069\u61c9\u73fe\u8c61\uff0c\u7a31\u70ba\u6c83\u4f2f\u683c\u6548\u61c9 (Warburg Effect)\u3002\u9019\u7a2e\u73fe\u8c61\u63cf\u8ff0\u4e86\u764c\u7d30\u80de\u904e\u9ad8\u7684\u7cd6\u9175\u89e3\u901f\u7387\uff0c\u5373\u4f7f\u5728\u6709\u6c27\u7684\u60c5\u6cc1\u4e0b\uff0c\u4e5f\u80fd\u4ee5\u7d04\u6b63\u5e38\u7d30\u80de 200 \u500d\u7684\u901f\u7387\u6d88\u8017\u8461\u8404\u7cd6\u3002\u9019\u7a2e\u65b0\u9673\u4ee3\u8b1d\u7684\u5f31\u9ede\u70ba\u816b\u7624\u5b78\u958b\u95e2\u4e86\u65b0\u7684\u6cbb\u7642\u7a97\u53e3\uff0c\u4f8b\u5982 AllCancer \u7a81\u7834\u6027\u7684\u65b0\u9673\u4ee3\u8b1d\u6cbb\u7642\uff0c\u5728\u6211\u5011\u8457\u540d\u7684 4D \u6cbb\u7642\u4e2d\u5c31\u6709\u4ecb\u7d39\u3002<\/p>\n

    \n
  • \u8f03\u9ad8\u7684\u7cd6\u9175\u89e3\u6d3b\u6027\u53ef\u78ba\u4fdd\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5 (AML) \u7d30\u80de\u7684\u5feb\u901f\u751f\u9577\u8207\u589e\u6b96\u3002<\/li>\n
  • \u91dd\u5c0d\u6027\u65b0\u9673\u4ee3\u8b1d\u6cbb\u7642\u5229\u7528\u9019\u7a2e\u8461\u8404\u7cd6\u4f9d\u8cf4\u6027\uff0c\u5c0d\u764c\u7d30\u80de\u7522\u751f\u9078\u64c7\u6027\u6bd2\u6027\u3002<\/li>\n<\/ul>\n

    \u5728 AllCancer\uff0c\u53d7 James P. Allison \u535a\u58eb\u548c Gregg L. Semenza \u535a\u58eb\u7b49\u8afe\u8c9d\u723e\u734e\u5f97\u4e3b\u7684\u555f\u767c\uff0c\u6211\u5011\u7684\u4ee3\u8b1d\u816b\u7624\u5b78\u5718\u968a\u5728\u674e\u570b\u83ef\u535a\u58eb\u7b49\u5148\u9a45\u5c08\u5bb6\u7684\u9818\u5c0e\u4e0b\uff0c\u5df2\u6210\u529f\u5730\u5c07\u4ee3\u8b1d\u9776\u5411\u6574\u5408\u5230 AML \u6cbb\u7642\u65b9\u6848\u4e2d\u3002<\/p>\n

    \u9999\u6e2f\u53ca\u4e9e\u6d32\u7684\u666e\u904d\u7a0b\u5ea6\u53ca\u5340\u57df\u5f71\u97ff<\/h3>\n

    \u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54 2024 \u5e74\u7684\u6578\u64da\uff0c\u5168\u7403\u6bcf\u5e74\u6709\u8d85\u904e 150,000 \u4eba\u7f79\u60a3\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML)\u3002\u5728\u9999\u6e2f\uff0c\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u69cb\u6210\u6210\u4eba\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u91cd\u8981\u90e8\u5206\uff0c\u672c\u5730\u7684\u767c\u75c5\u6578\u64da\u6307\u51fa\uff0c\u6bcf\u5e74\u8a3a\u65b7\u51fa\u7684\u767d\u8840\u75c5\u75c5\u4f8b\u4e2d\uff0c\u7d04\u6709 25-30% \u662f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u75c5\u4f8b\u3002<\/p>\n

    \u5728\u4e9e\u6d32\u4eba\u53e3\u4e2d\uff0c\u51fa\u73fe\u4e86\u4e0d\u540c\u7684\u6d41\u884c\u75c5\u5b78\u6a21\u5f0f\uff0c\u7a81\u986f\u4e86\u907a\u50b3\u6613\u611f\u6027\u548c\u74b0\u5883\u5f71\u97ff\u3002\u7814\u7a76\u986f\u793a\uff0c\u5e74\u9577\u65cf\u7fa4\uff0c\u7279\u5225\u662f 60 \u6b72\u4ee5\u4e0a\u7684\u65cf\u7fa4\u4e2d\uff0c\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u75c5\u4f8b\u6709\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u9019\u8868\u793a\u6211\u5011\u6025\u9700\u52a0\u5f37\u8a3a\u65b7\u7b56\u7565\u3001\u5168\u9762\u7684\u75c5\u60a3\u6559\u80b2\u4ee5\u53ca\u53ef\u6301\u7e8c\u7684\u9810\u9632\u653f\u7b56\u3002<\/p>\n

    \u6b64\u5916\uff0c\u4e9e\u6d32\u4eba\u53e3\u4e2d\u666e\u904d\u5b58\u5728\u7684\u7368\u7279\u57fa\u56e0\u7a81\u8b8a\u548c\u98a8\u96aa\u7279\u5fb5\u5f37\u8abf\u4e86\u500b\u6027\u5316\u65b9\u6cd5\u7684\u5fc5\u8981\u6027\u3002\u4f8b\u5982\uff0c\u9999\u6e2f\u7684\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u8a3a\u6240\u5df2\u767c\u73fe FLT3-ITD \u548c NPM1 \u57fa\u56e0\u7a81\u8b8a\u7b49\u907a\u50b3\u6a19\u8a18\uff0c\u9019\u4fc3\u4f7f AllCancer \u7b49\u9802\u5c16\u4e2d\u5fc3\u9032\u884c\u5c08\u9580\u7684\u7be9\u6aa2\u8a08\u756b\u548c\u500b\u4eba\u5316\u6cbb\u7642\u3002<\/p>\n

    \u5c0d\u75c5\u60a3\u7684\u8eab\u5fc3\u5f71\u97ff<\/h3>\n

    \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u5f71\u97ff\u4e0d\u53ea\u662f\u751f\u7406\u4e0a\u7684\u6311\u6230\u3002\u60a3\u8005\u901a\u5e38\u6703\u7d93\u6b77\u96e3\u4ee5\u627f\u64d4\u7684\u60c5\u7dd2\u548c\u5fc3\u7406\u8ca0\u64d4\uff0c\u4f8b\u5982\u7126\u616e\u3001\u4e0d\u78ba\u5b9a\u6027\u3001\u5bb3\u6015\u5fa9\u767c\uff0c\u4ee5\u53ca\u65e5\u5e38\u751f\u6d3b\u6c34\u6e96\u56b4\u91cd\u53d7\u640d\uff1a<\/p>\n

      \n
    • \u8eab\u9ad4\u72c0\u6cc1\uff1a\u56b4\u91cd\u75b2\u52de\u3001\u4e0d\u660e\u539f\u56e0\u7684\u9ad4\u91cd\u4e0b\u964d\u3001\u514d\u75ab\u529b\u4e0b\u964d\u5c0e\u81f4\u7684\u53cd\u8986\u611f\u67d3\u3001\u7d93\u5e38\u7600\u9752\u548c\u7570\u5e38\u51fa\u8840\u3002<\/li>\n
    • \u60c5\u7dd2\u65b9\u9762\uff1a\u5b64\u7acb\u611f\u3001\u6291\u9b31\u3001\u5c0d\u6cbb\u7642\u7d50\u679c\u7684\u7126\u616e\uff0c\u4ee5\u53ca\u5c0d\u751f\u6d3b\u65b9\u5f0f\u6539\u8b8a\u7684\u9867\u616e\u3002<\/li>\n<\/ul>\n

      \u6211\u5011\u7684\u5168\u65b9\u4f4d\u652f\u63f4\u670d\u52d9\u5305\u62ec\u5c08\u9580\u7684\u5fc3\u7406\u8aee\u8a62\u3001\u75c5\u60a3\u6b0a\u76ca\u5718\u9ad4\u548c\u7d9c\u5408\u5c45\u5bb6\u6cbb\u7642\uff0c\u4ee5\u300c\u5148\u6cbb\u75c5\u3001\u5f8c\u4ed8\u6b3e\u300d\u7684\u653f\u7b56\u52a0\u5f37\u6211\u5011\u7684\u95dc\u61f7\u3002<\/p>\n

      \u77ad\u89e3\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u5206\u671f\u8207\u8a3a\u65b7<\/h3>\n

      \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u8a3a\u65b7\u4e3b\u8981\u5305\u62ec\u5916\u5468\u8840\u5206\u6790\u3001\u9aa8\u9ad3\u6d3b\u6aa2\u3001\u57fa\u56e0\u6aa2\u6e2c\u548c\u5f71\u50cf\u6280\u8853\u3002\u5206\u671f\u904e\u7a0b\u6703\u8003\u616e\u8a31\u591a\u56e0\u7d20\uff0c\u5305\u62ec\u7d30\u80de\u5206\u5316\u7a0b\u5ea6\u3001\u67d3\u8272\u9ad4\u7570\u5e38\u4ee5\u53ca\u75c5\u60a3\u7684\u6574\u9ad4\u5065\u5eb7\u72c0\u6cc1\u3002\u65e9\u671f\u767c\u73fe\u548c\u6e96\u78ba\u5206\u671f\u53ef\u986f\u8457\u6539\u5584\u6cbb\u7642\u6548\u679c\u548c\u75c5\u60a3\u9810\u5f8c\u3002<\/p>\n

      \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u6210\u56e0\u8207\u98a8\u96aa\u56e0\u7d20<\/h2>\n

      \u5f71\u97ff AML \u7684\u907a\u50b3\u56e0\u7d20<\/h3>\n

      \u77ad\u89e3\u907a\u50b3\u50be\u5411\u5c0d\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u6cbb\u7642\u8d77\u8457\u95dc\u9375\u4f5c\u7528\u3002\u5f71\u97ff\u767d\u8840\u75c5\u767c\u75c5\u7684\u907a\u50b3\u56e0\u7d20\u5305\u62ec\u8207\u8f03\u9ad8\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u98a8\u96aa\u76f8\u95dc\u7684\u907a\u50b3\u7d9c\u5408\u75c7\uff0c\u5982 Fanconi \u8ca7\u8840\u548c Down \u7d9c\u5408\u75c7\u3002FLT3\u3001NPM1 \u548c CEBPA \u7b49\u57fa\u56e0\u7684\u7a81\u8b8a\u7d93\u5e38\u6d89\u53ca AML \u7684\u767c\u75c5\u6a5f\u5236\uff0c\u4e0d\u540c\u75c5\u60a3\u7684\u60c5\u6cc1\u6703\u5f71\u97ff\u9810\u5f8c\u548c\u6cbb\u7642\u53cd\u61c9\u3002<\/p>\n

        \n
      • NPM1 \u57fa\u56e0\u7a81\u8b8a\u8868\u793a\u9810\u5f8c\u826f\u597d\u3002<\/li>\n
      • FLT3 \u5167\u90e8\u4e32\u806f\u91cd\u758a (FLT3-ITD) \u8207\u4fb5\u8972\u6027\u75c5\u7a0b\u6709\u95dc\uff0c\u4e26\u5df2\u6210\u70ba\u6cbb\u7642\u76ee\u6a19\u3002<\/li>\n<\/ul>\n

        \u5289\u570b\u9f8d\u6559\u6388\u9818\u5c0e\u7684\u7814\u7a76\u5c0d\u6574\u500b\u4e9e\u6d32\u7684\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u8a3a\u65b7\u548c\u6cbb\u7642\u7b56\u7565\u7522\u751f\u4e86\u986f\u8457\u7684\u5f71\u97ff\uff0c\u7a81\u986f\u4e86\u57fa\u56e0\u7be9\u67e5\u5728\u91dd\u5c0d\u9999\u6e2f\u8a3a\u6240\u5e38\u898b\u7684\u57fa\u56e0\u7279\u5fb5\u958b\u767c\u500b\u6027\u5316\u6cbb\u7642\u4e2d\u7684\u95dc\u9375\u4f5c\u7528\u3002<\/p>\n

        \u74b0\u5883\u548c\u751f\u6d3b\u65b9\u5f0f\u98a8\u96aa\u56e0\u7d20<\/h3>\n

        \u74b0\u5883\u66b4\u9732\u5c0d\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u767c\u5c55\u6709\u91cd\u5927\u5f71\u97ff\u3002\u4e3b\u8981\u81f4\u75c5\u56e0\u5b50\u5305\u62ec\uff1a<\/p>\n

          \n
        • \u66fe\u56e0\u764c\u75c7\u6cbb\u7642\u800c\u63a5\u89f8\u653e\u5c04\u7dda\u548c\u5316\u5b78\u7642\u6cd5\uff0c\u7279\u5225\u662f\u70f7\u5316\u5242\u548c\u653e\u5c04\u7dda\u6cbb\u7642\u3002<\/li>\n
        • \u82ef\u63a5\u89f8\uff0c\u8207 AML \u75c5\u4f8b\u5bc6\u5207\u76f8\u95dc\u7684\u5de5\u696d\u5316\u5b78\u54c1\u63a5\u89f8\u8a18\u9304\u3002<\/li>\n
        • \u8207\u81f4\u764c\u5316\u5408\u7269\u76f8\u95dc\u7684\u9577\u671f\u5438\u7159\u7fd2\u6163\u589e\u52a0\u4e86\u767d\u8840\u75c5\u7684\u767c\u75c5\u7387\u3002<\/li>\n<\/ul>\n

          \u80a5\u80d6\u548c\u9577\u671f\u98f2\u9152\u7b49\u751f\u6d3b\u578b\u614b\u56e0\u7d20\u6703\u9020\u6210\u65b0\u9673\u4ee3\u8b1d\u58d3\u529b\uff0c\u5f71\u97ff\u514d\u75ab\u53cd\u61c9\uff0c\u4e26\u53ef\u80fd\u4fc3\u9032\u767d\u8840\u75c5\u7d30\u80de\u7684\u5f62\u6210\u3002\u5f37\u8abf\u4fdd\u6301\u5065\u5eb7\u9ad4\u91cd\u548c\u6212\u83f8\u7b49\u9810\u9632\u6027\u751f\u6d3b\u65b9\u5f0f\u7684\u8abf\u6574\uff0c\u53ef\u5927\u5e45\u964d\u4f4e\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u98a8\u96aa\u3002<\/p>\n

          \u4ee3\u8b1d\u8106\u5f31\u6027\u8207\u6cbb\u7642\u5275\u65b0<\/h3>\n

          AML \u7d30\u80de\u4f9d\u8cf4\u65b0\u9673\u4ee3\u8b1d\u9014\u5f91\uff0c\u4e3b\u8981\u662f\u8461\u8404\u7cd6\u548c\u8c37\u6c28\u9170\u80fa\uff0c\u4ee5\u7dad\u6301\u7d30\u80de\u7684\u5feb\u901f\u589e\u6b96\u3002AllCancer \u9769\u547d\u6027\u7684 4D \u4ee3\u8b1d\u7642\u6cd5\u76f4\u63a5\u5229\u7528\u9019\u4e9b\u4f9d\u8cf4\u6027\uff0c\u64fe\u4e82\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7d30\u80de\u6240\u5fc5\u9700\u7684\u95dc\u9375\u9175\u7d20\u53cd\u61c9\uff0c\u4e26\u4fdd\u8b77\u5065\u5eb7\u7d44\u7e54\u3002\u8afe\u8c9d\u723e\u734e\u5f97\u4e3b Gregg Semenza \u535a\u58eb\u7b49\u4eba\u5df2\u5f37\u8abf\u764c\u75c7\u65b0\u9673\u4ee3\u8b1d\u7684\u91cd\u8981\u89c0\u9ede\uff0c\u800c\u6211\u5011\u7684\u7642\u6cd5\u5df2\u5168\u9762\u7d50\u5408\u9019\u4e9b\u89c0\u9ede\uff0c\u7b26\u5408 FDA \u548c EMA \u6a19\u6e96\uff0c\u4e26\u5df2\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u3001\u65e5\u672c\u548c\u4e2d\u570b\u7b49\u5168\u7403\u5404\u5730\u8a3b\u518a\u5c08\u5229\u3002<\/p>\n

          \u5982\u9700\u9032\u884c\u500b\u4eba\u5316\u8a55\u4f30\u4e26\u63a2\u8a0e AllCancer \u6700\u5148\u9032\u7684 AML 4D \u4ee3\u8b1d\u7642\u6cd5\uff0c\u6211\u5011\u8aa0\u646f\u5730\u9080\u8acb\u60a8\u7acb\u5373\u9810\u7d04\u8aee\u8a62\u3002\u6211\u5011\u7684 \u300c\u5148\u6cbb\u7652\uff0c\u5f8c\u4ed8\u6b3e \u300d\u653f\u7b56\u5f37\u8abf\u6211\u5011\u5c0d\u60a8\u7684\u7167\u8b77\u7684\u627f\u8afe\uff0c\u63d0\u9ad8\u81e8\u5e8a\u6210\u679c\u548c\u75c5\u4eba\u7684\u4fe1\u4efb\u3002<\/p>\n

          \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u75c7\u72c0<\/h2>\n

          \u53ca\u65e9\u767c\u73fe\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u75c7\u72c0\uff0c\u53ef\u5927\u5e45\u589e\u52a0\u6210\u529f\u8655\u7406\u548c\u6cbb\u7642\u7684\u6a5f\u6703\u3002\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u75c7\u72c0\u6e90\u65bc\u529f\u80fd\u5931\u5e38\u7684\u767d\u8840\u75c5\u7d30\u80de\u5728\u9aa8\u9ad3\u4e2d\u4e0d\u53d7\u63a7\u5236\u5730\u589e\u6b96\uff0c\u5c0e\u81f4\u6b63\u5e38\u8840\u7d30\u80de\u88fd\u9020\u529f\u80fd\u53d7\u640d\u3002\u77ad\u89e3\u9019\u4e9b\u660e\u986f\u7684\u75c7\u72c0\uff0c\u5c0d\u8a3a\u65b7\u3001\u9810\u5f8c\u548c\u6cbb\u7642\u9078\u64c7\u90fd\u6709\u6df1\u9060\u7684\u5f71\u97ff\u3002<\/p>\n

          \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u5e38\u898b\u75c7\u72c0<\/h3>\n

          \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u75c7\u72c0\u6700\u521d\u53ef\u80fd\u5f88\u6a21\u7cca\uff0c\u8207\u5e38\u898b\u7684\u611f\u67d3\u76f8\u4f3c\uff0c\u56e0\u6b64\u96e3\u4ee5\u7acb\u5373\u8b58\u5225\u3002\u5e38\u898b\u7684\u75c7\u72c0\u5305\u62ec<\/p>\n

            \n
          • \u56e0\u6b63\u5e38\u7d05\u8840\u7403\u88fd\u9020\u4e0d\u8db3\u800c\u5f15\u8d77\u8ca7\u8840\uff0c\u5c0e\u81f4\u75b2\u52de\u548c\u865b\u5f31\u3002<\/li>\n
          • \u7531\u65bc\u767d\u8840\u75c5\u767d\u7d30\u80de\u7834\u58de\u6b63\u5e38\u7684\u514d\u75ab\u9632\u79a6\uff0c\u9020\u6210\u983b\u7e41\u4e14\u6301\u7e8c\u7684\u611f\u67d3\u3002<\/li>\n
          • \u767c\u71d2\u3001\u767c\u51b7\u6216\u985e\u4f3c\u6d41\u611f\u7684\u75c7\u72c0\u6bd4\u4e00\u822c\u611f\u67d3\u6301\u7e8c\u66f4\u4e45\u3002<\/li>\n
          • \u610f\u6599\u4e4b\u5916\u7684\u9ad4\u91cd\u4e0b\u964d\uff0c\u7279\u5fb5\u662f\u8207\u98f2\u98df\u6216\u904b\u52d5\u7121\u95dc\u7684\u9ad4\u91cd\u5927\u5e45\u4e0b\u964d\u3002<\/li>\n
          • \u56e0\u8840\u5c0f\u677f\u6578\u91cf\u4f4e\u800c\u5bb9\u6613\u7600\u50b7\u6216\u81ea\u767c\u6027\u51fa\u8840\u3002<\/li>\n
          • \u7279\u5225\u662f\u6307\u7532\u3001\u7259\u9f66\u6216\u819a\u8272\u986f\u5f97\u84bc\u767d\u6216\u84bc\u767d\u3002<\/li>\n
          • \u547c\u5438\u6025\u4fc3\uff0c\u8f15\u5fae\u9ad4\u529b\u6d3b\u52d5\u6703\u52a0\u91cd\u3002<\/li>\n
          • \u56e0\u9aa8\u9ad3\u4e2d\u7684\u767d\u8840\u75c5\u7d30\u80de\u64f4\u6563\u800c\u7e7c\u767c\u7684\u95dc\u7bc0\u75db\u3001\u9aa8\u75db\u6216\u89f8\u75db\u3002<\/li>\n
          • \u76dc\u6c57\u548c\u4e0d\u5c0b\u5e38\u7684\u71b1\u611f\uff0c\u5373\u4f7f\u5728\u4f11\u606f\u6642\u4e5f\u662f\u5982\u6b64\u3002<\/li>\n
          • \u9838\u90e8\u3001\u814b\u4e0b\u548c\u8179\u80a1\u6e9d\u5340\u6dcb\u5df4\u7d50\u816b\u5927\u3002<\/li>\n<\/ul>\n

            \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u7279\u5b9a\u968e\u6bb5\u75c7\u72c0<\/h3>\n

            \u75c7\u72c0\u6703\u56e0\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u968e\u6bb5\u548c\u75be\u75c5\u9032\u5c55\u800c\u6709\u6240\u4e0d\u540c\uff1a<\/p>\n

              \n
            • \u65e9\u671f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a<\/strong> \u4e3b\u8981\u662f\u75b2\u52de\u3001\u7d93\u5e38\u611f\u67d3\u3001\u8f15\u5fae\u767c\u71d2\u6216\u5bb9\u6613\u7600\u50b7\u3002\u9019\u4e9b\u75c7\u72c0\u5f88\u5fae\u5999\uff0c\u5e38\u8207\u8f03\u8f15\u5fae\u7684\u75c5\u75c7\u6df7\u6dc6\u3002<\/li>\n
            • \u9032\u968e AML\uff1a<\/strong> \u5305\u62ec\u56b4\u91cd\u8ca7\u8840\uff0c\u5c0e\u81f4\u8eab\u9ad4\u6975\u5ea6\u865b\u5f31\u3001\u514d\u75ab\u529b\u660e\u986f\u4e0b\u964d\u3001\u56b4\u91cd\u611f\u67d3\u3001\u6301\u7e8c\u9ad8\u71d2\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u4f34\u6709\u56b4\u91cd\u51fa\u8840\u554f\u984c\uff0c\u4ee5\u53ca\u9ad4\u91cd\u4e0b\u964d\u554f\u984c\u3002<\/li>\n
            • \u665a\u671f AML\uff1a<\/strong> \u9ad4\u91cd\u548c\u808c\u8089\u91cf\u660e\u986f\u4e0b\u964d\u3001\u547c\u5438\u7a98\u8feb\u3001\u986f\u8457\u51fa\u8840\u767c\u4f5c\u3001\u813e\u81df\u6216\u809d\u81df\u816b\u5927\uff0c\u4ee5\u53ca\u5feb\u901f\u764c\u7d30\u80de\u8ca0\u8377\u7684\u4f75\u767c\u75c7\uff0c\u5305\u62ec\u4ee3\u8b1d\u5931\u8861\u3002<\/li>\n<\/ul>\n

              \u9019\u4e9b\u81e8\u5e8a\u8868\u73fe\u53cd\u6620\u51fa\u9aa8\u9ad3\u6b63\u5e38\u7d30\u80de\u529f\u80fd\u7684\u6839\u672c\u6027\u751f\u7269\u969c\u7919\uff0c\u4e3b\u8981\u662f\u53d7\u5230\u764c\u7d30\u80de\u4f9d\u8cf4\u7570\u5e38\u8461\u8404\u7cd6\u4ee3\u8b1d\uff08\u6c83\u4f2f\u683c\u6548\u61c9\uff09\u7684\u5f71\u97ff\u3002\u53ca\u6642\u8b58\u5225\u548c\u4ecb\u5165\u6cbb\u7642\u4ecd\u7136\u975e\u5e38\u91cd\u8981\uff0c\u53ef\u986f\u8457\u5f71\u97ff\u9810\u5f8c\u7d50\u679c\u3002<\/p>\n

              AML \u65e9\u671f\u8a3a\u65b7\u7684\u91cd\u8981\u6027<\/h3>\n

              \u65e9\u671f\u8a3a\u65b7\u53ef\u5927\u5e45\u6539\u5584\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u6cbb\u7642\u6548\u679c\u3002\u5982\u679c\u60a8\u6216\u60a8\u7684\u5bb6\u4eba\u767c\u73fe\u6301\u7e8c\u6027\u3001\u4e0d\u660e\u539f\u56e0\u7684\u767d\u8840\u75c5\u5fb5\u5146\u6216\u75c7\u72c0\uff0c\u8acb\u7acb\u5373\u8aee\u8a62\u91ab\u7642\u4fdd\u5065\u63d0\u4f9b\u8005\u3002\u5728\u6211\u5011\u7684 AllCancer Clinic\uff0c\u65e9\u671f\u8a3a\u65b7\u6709\u52a9\u65bc\u7372\u5f97\u5275\u65b0\u7684\u6cbb\u7642\uff0c\u4f8b\u5982\u4ee3\u8b1d\u9776\u5411\u6cbb\u7642\u548c\u7cbe\u78ba\u7684\u500b\u4eba\u5316\u91ab\u7642\u5e72\u9810\u3002<\/p>\n

              \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u5206\u671f\u8207\u5b58\u6d3b\u7387<\/h2>\n

              \u77ad\u89e3\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u5206\u671f\u548c\u76f8\u5c0d\u61c9\u7684\u5b58\u6d3b\u7387\uff0c\u53ef\u63d0\u4f9b\u6e05\u6670\u7684\u8cc7\u8a0a\u548c\u4fdd\u8b49\uff0c\u8b93\u60a3\u8005\u548c\u5bb6\u5c6c\u80fd\u5920\u505a\u51fa\u660e\u667a\u7684\u6c7a\u5b9a\u3002\u8b93\u6211\u5011\u4ee5\u9999\u6e2f\u548c\u4e9e\u6d32\u7684\u5177\u9ad4\u6578\u64da\u4f86\u63a2\u8a0e\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u5206\u671f\uff0c\u4ee5\u63d0\u4f9b\u53cd\u6620\u5340\u57df\u6558\u8ff0\u7684\u7cbe\u78ba\u6307\u5357\u3002<\/p>\n

              \u7b2c 1 \u968e\u6bb5\uff1a \u65e9\u671f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u7279\u5fb5\u8207\u9810\u5f8c<\/h3>\n

              \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (Acute Myeloid Leukemia) \u7b2c 1 \u671f\u7684\u7279\u5fb5\u662f\u6700\u521d\u7684\u60e1\u6027\u8f49\u8b8a\u4e3b\u8981\u5c40\u9650\u65bc\u9aa8\u9ad3\u548c\u5468\u908a\u8840\u6db2\uff1a<\/p>\n

                \n
              • \u6bcd\u7d30\u80de\u767e\u5206\u6bd4\u53ef\u80fd\u8f15\u5fae\u5347\u9ad8\uff0c\u4f46\u4e0d\u6703\u5ee3\u6cdb\u6d78\u6f64\u3002<\/li>\n
              • \u75c7\u72c0\u5f80\u5f80\u662f\u5fae\u5999\u4e14\u975e\u7279\u7570\u7684\uff0c\u53ef\u6b78\u56e0\u65bc\u8f15\u5fae\u7684\u7d30\u80de\u7834\u58de\u3002<\/li>\n
              • \u5177\u6709\u6709\u5229\u9810\u5f8c\u5206\u5b50\u56e0\u7d20\u7684\u6cbb\u7642\u53cd\u61c9\u901a\u5e38\u8f03\u9ad8\u3002<\/li>\n<\/ul>\n

                \u7531\u65bc\u79d1\u6280\u7684\u9032\u6b65\u3001\u5ee3\u6cdb\u7684\u5340\u57df\u6027\u5065\u5eb7\u5ba3\u50b3\u6d3b\u52d5\u5e36\u4f86\u7684\u53ca\u6642\u8a3a\u65b7\uff0c\u4ee5\u53ca\u7cbe\u78ba\u7642\u6cd5\u7684\u6709\u6548\u904b\u7528\uff0c\u9999\u6e2f\u548c\u4e9e\u6d32\u65e9\u671f\u8a3a\u65b7\u548c\u6cbb\u7642\u60a3\u8005\u7684\u5b58\u6d3b\u7387\u901a\u5e38\u9ad8\u65bc\u5168\u7403\u5e73\u5747\u6c34\u5e73\u3002\u53d7\u6709\u6548\u7684\u591a\u5b78\u79d1\u6cbb\u7642\u65b9\u6848\u5f71\u97ff\uff0c\u65e9\u671f\u6025\u6027\u9ad3\u7d30\u80de\u816b\u7624\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u5f98\u5f8a\u5728 50-70% \u5de6\u53f3\u3002<\/p>\n

                \u7b2c 2 \u968e\u6bb5\uff1a \u4e2d\u5ea6\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u9032\u5c55\u8207\u6cbb\u7642\u65b9\u6848<\/h3>\n

                \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u9032\u5c55\u7684\u4e2d\u671f\u968e\u6bb5\u4ee3\u8868\u8457\u66f4\u5927\u7684\u75be\u75c5\u8ca0\u64d4\u548c\u5411\u5468\u908a\u74b0\u5883\u64f4\u6563\u7684\u53ef\u80fd\u6027\uff1a<\/p>\n

                  \n
                • \u89c0\u5bdf\u5230\u5faa\u74b0\u4e2d\u7684\u7206\u70b8\u7d30\u80de\u589e\u52a0\uff0c\u9aa8\u9ad3\u4e2d\u7684\u7570\u5e38\u7d30\u80de\u8a08\u6578\u5347\u9ad8\u3002<\/li>\n
                • \u53cd\u6620\u8840\u5c0f\u677f\u88fd\u9020\u91cf\u6e1b\u5c11\u548c\u514d\u75ab\u529b\u53d7\u640d\u7684\u81e8\u5e8a\u5f71\u97ff\u3002<\/li>\n
                • \u5bc6\u96c6\u5316\u7642\u3001\u91dd\u5c0d\u6027\u4ee3\u8b1d\u6cbb\u7642\u548c\u751f\u7269\u6cbb\u7642\u662f\u7ba1\u7406\u7b56\u7565\u7684\u6838\u5fc3\u3002<\/li>\n<\/ul>\n

                  2 \u671f AML \u5728 5 \u5e74\u671f\u7684\u5e73\u5747\u5b58\u6d3b\u7387\u4ecb\u65bc 40-60% \u4e4b\u9593\uff0c\u4e0d\u904e\u7cbe\u5bc6\u4ee3\u8b1d\u7642\u6cd5\u6b63\u5728\u9010\u6f38\u63d0\u5347\u9019\u4e9b\u6578\u5b57\u3002<\/p>\n

                  \u7b2c 3 \u671f\uff1a\u665a\u671f\u75be\u75c5\uff0c\u9aa8\u9ad3\u5ee3\u6cdb\u53d7\u640d<\/h3>\n

                  \u7b2c 3 \u671f\u7684\u4e3b\u8981\u7279\u5fb5\u662f\u5ee3\u6cdb\u7684\u9aa8\u9ad3\u66ff\u4ee3\u3001\u5065\u5eb7\u7d30\u80de\u660e\u986f\u6e1b\u5c11\uff0c\u4ee5\u53ca\u65e9\u671f\u7684\u5168\u7cfb\u7d71\u5f71\u97ff\uff1a<\/p>\n

                    \n
                  • \u56b4\u91cd\u7684\u8ca7\u8840\u901a\u5e38\u6703\u6709\u660e\u986f\u7684\u75c7\u72c0\uff0c\u5f71\u97ff\u75c5\u60a3\u7684\u5065\u5eb7\u3002<\/li>\n
                  • \u591a\u6a21\u5f0f\u6cbb\u7642 - \u5305\u62ec\u5316\u7642\u3001\u9aa8\u9ad3\u79fb\u690d\u3001\u514d\u75ab\u7642\u6cd5\u548c\u4ee3\u8b1d\u5e72\u9810 - \u8b8a\u5f97\u4e0d\u53ef\u6216\u7f3a\u3002<\/li>\n
                  • \u900f\u904e\u7cbe\u78ba\u7684\u500b\u4eba\u5316\u898f\u5283\u548c\u983b\u7e41\u7684\u76e3\u6e2c\u9032\u884c\u5168\u9762\u7167\u8b77\uff0c\u6709\u52a9\u65bc\u63d0\u9ad8\u5b58\u6d3b\u7387\uff0c\u76ee\u524d\u4e94\u5e74\u7684\u5b58\u6d3b\u7387\u4ecb\u65bc 30-50% \u4e4b\u9593\u3002<\/li>\n<\/ul>\n

                    \u7b2c\u56db\u968e\u6bb5\uff1a\u8f49\u79fb\u6027\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5-\u6311\u6230\u3001\u5275\u65b0\u8207\u751f\u5b58\u5c55\u671b<\/h3>\n

                    \u7b2c 4 \u671f AML \u5305\u62ec\u5ee3\u6cdb\u7684\u8f49\u79fb\u60c5\u6cc1\u548c\u5168\u8eab\u6027\u53d7\u7d2f\uff0c\u4e26\u4f34\u6709\u56b4\u91cd\u7684\u81e8\u5e8a\u75c7\u72c0\uff1a<\/p>\n

                      \n
                    • \u767d\u8840\u75c5\u7d30\u80de\u5728\u5404\u500b\u5668\u5b98\uff08\u76ae\u819a\u3001\u809d\u81df\u3001\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\uff09\u51fa\u73fe\u986f\u8457\u800c\u5ee3\u6cdb\u7684\u6d78\u6f64\u3002<\/li>\n
                    • \u8907\u96dc\u7684\u5168\u8eab\u6027\u8868\u73fe\uff0c\u5305\u62ec\u51fa\u8840\u6027\u75be\u75c5\u3001\u611f\u67d3\u3001\u5668\u5b98\u640d\u50b7\uff0c\u4ee5\u53ca\u660e\u986f\u5177\u6709\u6311\u6230\u6027\u7684\u8840\u6db2\u5b78\u554f\u984c\u3002<\/li>\n
                    • \u7d50\u5408\u65b0\u578b 4D \u91dd\u5c0d\u6027\u4ee3\u8b1d\u7642\u6cd5\u7684\u5168\u8eab\u6027\u6cbb\u7642\u8207\u5148\u9032\u7684\u652f\u63f4\u7167\u8b77\u63aa\u65bd\uff0c\u63d0\u4f9b\u4e86\u5275\u65b0\u7684\u6cbb\u7642\u66ff\u4ee3\u65b9\u6848\u3002<\/li>\n
                    • \u5b58\u6d3b\u7387\u6b77\u4f86\u7dad\u6301\u5728 10-30% \u5de6\u53f3\uff0c\u96d6\u7136\u7d50\u5408\u5275\u65b0\u6280\u8853\u7684\u6539\u5584\u6709\u5e0c\u671b\u5c07\u75c5\u60a3\u7684\u7d50\u679c\u63d0\u5347\u81f3\u6162\u6027\u75be\u75c5\u7ba1\u7406\u72c0\u614b\u3002<\/li>\n<\/ul>\n

                      \u63a1\u7528\u5148\u9032\u7684\u5275\u65b0\u6cbb\u7642\u65b9\u6cd5\uff0c\u53ef\u78ba\u4fdd AllCancer \u8a3a\u6240\u7684\u6cbb\u7642\u6548\u679c\u6709\u986f\u8457\u6539\u5584\u7684\u524d\u666f\uff0c\u4e26\u4fc3\u9032 AML \u7b2c 4 \u671f\u8b77\u7406\u7ba1\u7406\u7684\u6f5b\u5728\u6162\u6027\u5316\u3002<\/p>\n

                      \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u6cbb\u7642\u65b9\u6848<\/h2>\n

                      \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u6cbb\u7642\u9078\u64c7\u662f\u6839\u64da\u75c5\u60a3\u7684\u5e74\u9f61\u3001\u5065\u5eb7\u72c0\u6cc1\u3001\u57fa\u56e0\u7a81\u8b8a\u548c\u767d\u8840\u75c5\u7684\u81e8\u5e8a\u7279\u6027\u4f86\u6c7a\u5b9a\u7684\u3002AML \u901a\u5e38\u5177\u6709\u4fb5\u8972\u6027\uff0c\u500b\u4eba\u5316\u7684\u6cbb\u7642\u7b56\u7565\u5c0d\u65bc\u6539\u5584\u7642\u6548\u548c\u751f\u6d3b\u54c1\u8cea\u81f3\u95dc\u91cd\u8981\u3002<\/p>\n

                      \u6a19\u6e96\u5316\u5b78\u6cbb\u7642<\/h3>\n

                      \u5316\u5b78\u6cbb\u7642\u4ecd\u662f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u6cbb\u7642\u7b56\u7565\u7684\u57fa\u77f3\uff0c\u901a\u5e38\u5305\u62ec\u8a98\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u548c\u978f\u56fa\u6027\u5316\u5b78\u6cbb\u7642\u3002<\/p>\n

                        \n
                      • \u5f15\u5c0e\u6cbb\u7642\uff1a<\/strong> \u901a\u5e38\u4f7f\u7528 Cytarabine (Ara-C) \u7d50\u5408 daunorubicin \u6216 idarubicin\uff0c\u7a31\u70ba\u6a19\u6e96\u300c7+3 \u65b9\u6848\u300d\u3002\u5176\u76ee\u7684\u662f\u900f\u904e\u5feb\u901f\u6e1b\u5c11\u767d\u8840\u75c5\u7d30\u80de\u4ee5\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u3002<\/li>\n
                      • \u978f\u56fa\u7642\u6cd5\uff1a<\/strong> \u9ad8\u5291\u91cf\u7684\u5316\u7642\uff0c\u901a\u5e38\u662f\u9ad8\u5291\u91cf\u7684\u963f\u7cd6\u80de\u82f7 (HiDAC)\uff0c\u76ee\u7684\u662f\u6d88\u9664\u5269\u9918\u7684\u767d\u8840\u75c5\u7d30\u80de\uff0c\u9632\u6b62\u5fa9\u767c\u3002<\/li>\n<\/ul>\n

                        \u653e\u5c04\u6cbb\u7642\u6ce8\u610f\u4e8b\u9805<\/h3>\n

                        \u653e\u5c04\u6cbb\u7642\u901a\u5e38\u4e0d\u662f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u7576\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7d30\u80de\u64f4\u6563\u81f3\u7279\u5b9a\u90e8\u4f4d\uff0c\u5982\u8166\u90e8\u6216\u810a\u690e\uff0c\u5c0e\u81f4\u795e\u7d93\u75c7\u72c0\u6642\uff0c\u624d\u6703\u63a1\u7528\u653e\u5c04\u6cbb\u7642\u3002\u4e5f\u53ef\u80fd\u5728\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d (HSCT) \u524d\u4f7f\u7528\u3002<\/p>\n

                        \u5148\u9032\u7684\u6cbb\u7642\u9078\u64c7\uff1a\u5e79\u7d30\u80de\u79fb\u690d<\/h3>\n

                        \u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d(HSCT)\u63d0\u4f9b\u4e86\u6f5b\u5728\u7684\u6839\u6cbb\u6027\u6cbb\u7642\uff0c\u7279\u5225\u662f\u5c0d\u65bc\u5316\u7642\u7de9\u89e3\u5f8c\u7684\u9ad8\u98a8\u96aa\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u75c5\u4f8b\u5f88\u6709\u5e6b\u52a9\u3002<\/p>\n

                          \n
                        • \u7570\u9ad4\u79fb\u690d\uff1a<\/strong> \u4f86\u81ea\u914d\u5c0d\u6350\u8d08\u8005\u7684\u5e79\u7d30\u80de\u53ef\u7522\u751f\u79fb\u690d\u7269\u6297\u767d\u8840\u75c5\u6548\u61c9\uff0c\u5927\u5e45\u964d\u4f4e\u5fa9\u767c\u98a8\u96aa\uff0c\u4f46\u4e5f\u6703\u7522\u751f\u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75be\u75c5 (GVHD) \u7b49\u4f75\u767c\u75c7\u3002<\/li>\n
                        • \u81ea\u9ad4\u79fb\u690d\uff1a<\/strong> \u904b\u7528\u75c5\u4eba\u5728\u7de9\u89e3\u671f\u9593\u6240\u7372\u5f97\u7684\u5e79\u7d30\u80de\u3002\u7531\u65bc\u5fa9\u767c\u98a8\u96aa\u8f03\u9ad8\uff0c\u6b64\u65b9\u6cd5\u8f03\u5c11\u7528\u65bc\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff0c\u4f46\u82e5\u6c92\u6709\u5339\u914d\u7684\u6350\u8d08\u8005\u53ef\u4f9b\u9078\u64c7\uff0c\u5247\u53ef\u8003\u616e\u4f7f\u7528\u3002<\/li>\n<\/ul>\n

                          \u6a19\u9776\u6cbb\u7642\u5275\u65b0<\/h3>\n

                          \u9776\u5411\u7642\u6cd5\u80fd\u7cbe\u78ba\u5730\u653b\u64ca\u767d\u8840\u75c5\u7d30\u80de\uff0c\u800c\u4e0d\u50b7\u5bb3\u5468\u570d\u7684\u5065\u5eb7\u7d44\u7e54\uff0c\u56e0\u6b64\u70ba\u764c\u75c7\u6cbb\u7642\u5e36\u4f86\u4e86\u9769\u547d\u6027\u7684\u6539\u8b8a\uff0c\u5c24\u5176\u662f\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u3002\u5176\u9078\u64c7\u4e3b\u8981\u53d6\u6c7a\u65bc\u7279\u5b9a\u7684\u57fa\u56e0\u7a81\u8b8a\u3002<\/p>\n

                            \n
                          • FLT3 \u6291\u5236\u5291\uff1a<\/strong> Midostaurin \u548c Gilteritinib \u7b49\u85e5\u7269\u91dd\u5c0d FLT3 \u57fa\u56e0\u7a81\u8b8a\u7684 AML\uff0c\u6539\u5584\u4e86\u5b58\u6d3b\u7387\u548c\u7de9\u89e3\u6642\u9593\u3002<\/li>\n
                          • IDH \u6291\u5236\u5291\uff1a<\/strong> Ivosidenib \u548c Enasidenib \u80fd\u6709\u6548\u89e3\u6c7a\u5177\u6709 IDH1\/IDH2\u7a81\u8b8a\u4e9e\u578b\u7684 AML\u3002<\/li>\n
                          • BCL-2 \u6291\u5236\u5291\uff1a<\/strong> Venetoclax \u8207\u8f03\u4f4e\u5291\u91cf\u7684\u5316\u7642\u85e5\u7269\u7d50\u5408\u4f7f\u7528\uff0c\u53ef\u986f\u8457\u63d0\u5347\u7642\u6548\uff0c\u5c0d\u5e74\u9577\u6216\u9ad4\u5f31\u7684\u75c5\u60a3\u5c24\u5176\u6709\u76ca\u3002<\/li>\n<\/ul>\n

                            \u91dd\u5c0d\u7d30\u80de\u4ee3\u8b1d\u7684\u65b0\u8208\u4ee3\u8b1d\u7642\u6cd5<\/h3>\n

                            AML \u7d30\u80de\u7684\u65b0\u9673\u4ee3\u8b1d\u4f9d\u8cf4\u6027\u63d0\u4f9b\u4e86\u4e00\u500b\u65b0\u7684\u6cbb\u7642\u524d\u6cbf\uff0c\u5176\u7279\u9ede\u662f\u660e\u986f\u4f9d\u8cf4\u65bc\u8461\u8404\u7cd6\u65b0\u9673\u4ee3\u8b1d\u7684\u6539\u8b8a (\u6c83\u4f2f\u683c\u6548\u61c9)\u3001\u8c37\u6c28\u9170\u80fa\u4f9d\u8cf4\u6027\u548c\u7dda\u7c92\u9ad4\u901a\u8def\u3002\u65b0\u8208\u7684\u65b9\u6cd5\u986f\u793a\u51fa\u91cd\u5927\u7684\u524d\u666f\uff1a<\/p>\n

                              \n
                            • \u8461\u8404\u7cd6\u651d\u53d6\u6291\u5236\u5291\uff1a<\/strong> \u963b\u65b7 GLUT1 \u548c GLUT3 \u8f49\u904b\u9ad4\u7684\u7814\u7a76\u65e5\u76ca\u9032\u6b65\uff0c\u9650\u5236\u8461\u8404\u7cd6\u4f9b\u61c9\uff0c\u9032\u800c\u640d\u5bb3\u764c\u7d30\u80de\u589e\u6b96\u3002<\/li>\n
                            • \u8c37\u6c28\u9170\u80fa\u4ee3\u8b1d\u5e72\u64fe\uff1a<\/strong> \u6291\u5236\u8c37\u6c28\u9170\u80fa\u9176\u548c\u76f8\u95dc\u4ee3\u8b1d\u9175\u7d20\u6703\u7834\u58de\u767d\u8840\u75c5\u7d30\u80de\u5229\u7528\u7684\u6b21\u8981\u91cd\u8981\u71df\u990a\u901a\u8def\uff0c\u964d\u4f4e\u5b58\u6d3b\u7387\u4e26\u589e\u52a0\u6cbb\u7642\u654f\u611f\u6027\u3002<\/li>\n<\/ul>\n

                              \u9999\u6e2f\u53ca\u4e9e\u6d32\u7684\u500b\u4eba\u5316\u6cbb\u7642\u898f\u5283<\/h3>\n

                              \u7531\u65bc\u5730\u57df\u548c\u7d93\u6fdf\u7684\u5dee\u7570\uff0c\u9999\u6e2f\u548c\u4e9e\u6d32\u5728\u6cbb\u7642\u6025\u6027\u9ad3\u7d30\u80de\u65b9\u9762\u7684\u9078\u64c7\u4ecd\u7136\u53d7\u5230\u9650\u5236\u3002\u5118\u7ba1\u5982\u6b64\uff0c\u8207\u6df1\u5733\u524d\u6d77\u6cf0\u5eb7\u53ca MD Anderson \u7b49\u9802\u5c16\u7814\u7a76\u6a5f\u69cb\u5408\u4f5c\u7684\u8a08\u5283\uff0c\u65e8\u5728\u900f\u904e\u5148\u9032\u7684\u500b\u4eba\u5316\u91ab\u7642\u65b9\u6cd5\uff0c\u7279\u5225\u91dd\u5c0d\u4e9e\u6d32\u4eba\u7684\u907a\u50b3\u7279\u5fb5\u548c\u4eba\u53e3\u7279\u5fb5\uff0c\u7e2e\u77ed\u5dee\u8ddd\u3002<\/p>\n

                              \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u50b3\u7d71\u7642\u6cd5\u7684\u9650\u5236<\/h2>\n

                              \u5316\u7642\u7684\u9ad8\u6bd2\u6027<\/h3>\n

                              \u5118\u7ba1\u5316\u5b78\u7642\u6cd5\u6709\u6548\uff0c\u4f46\u4ecd\u5b58\u5728\u986f\u8457\u7684\u7f3a\u9ede\u3002\u5316\u7642\u85e5\u7269\u7121\u5340\u5225\u5730\u653b\u64ca\u5065\u5eb7\u548c\u60e1\u6027\u7d30\u80de\uff0c\u9020\u6210\u76f8\u7576\u5927\u7684\u526f\u4f5c\u7528\uff0c\u5f71\u97ff\u75c5\u60a3\u7684\u751f\u6d3b\u54c1\u8cea\u548c\u6cbb\u7642\u4f9d\u8cf4\u6027\u3002<\/p>\n

                                \n
                              • \u9aa8\u9ad3\u6291\u5236\uff1a<\/strong> \u7d04\u6709 78% \u7684\u75c5\u60a3\u6703\u767c\u751f\uff0c\u5c0e\u81f4\u56b4\u91cd\u8ca7\u8840\u3001\u611f\u67d3\u548c\u51fa\u8840\u98a8\u96aa\uff0c\u901a\u5e38\u9700\u8981\u5bc6\u96c6\u7684\u91ab\u7642\u7ba1\u7406\u548c\u4f4f\u9662\u6cbb\u7642\u3002<\/li>\n
                              • \u5fc3\u81df\u6bd2\u6027\u548c\u5668\u5b98\u640d\u50b7\uff1a<\/strong> \u84bd\u74b0\u985e\u5316\u7642\u85e5\u7269 (daunorubicin, idarubicin) \u8207\u7d04 23% \u5fc3\u81df\u6bd2\u6027\u75c5\u4f8b\u6709\u95dc\uff0c\u53ef\u80fd\u5c0e\u81f4\u5fc3\u81df\u8870\u7aed\u548c\u9577\u671f\u5fc3\u8840\u7ba1\u75be\u75c5\u3002<\/li>\n<\/ul>\n

                                \u5c0d\u665a\u671f\u6216\u6297\u85e5\u6027\u75c5\u4f8b\u7642\u6548\u6709\u9650<\/h3>\n

                                \u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u5728\u665a\u671f\u968e\u6bb5\u4ecd\u7136\u5145\u6eff\u6311\u6230\uff0c\u7d93\u5178\u5316\u7642\u7684\u53cd\u61c9\u7387\u986f\u8457\u964d\u4f4e\uff08\u8f49\u79fb\u6027\u6216\u96e3\u6cbb\u6027\u75be\u75c5\u7684\u5ba2\u89c0\u53cd\u61c9<21%\uff09\uff0c\u7a81\u986f\u51fa\u8feb\u5207\u9700\u8981\u66f4\u6709\u6548\u7684\u7642\u6cd5\u3002<\/p>\n

                                \u653e\u5c04\u6cbb\u7642\u526f\u4f5c\u7528<\/h3>\n

                                \u8f3b\u5c04\u6703\u50b7\u5bb3\u5468\u570d\u7684\u5065\u5eb7\u7d44\u7e54\uff0c\u5c0e\u81f4\u6c38\u4e45\u6027\u50b7\u5bb3\u548c\u6162\u6027\u4f75\u767c\u75c7\u3002\u75c7\u72c0\u53ef\u80fd\u5305\u62ec\u75b2\u52de\u3001\u5641\u5fc3\u3001\u812b\u9aee\u3001\u76ae\u819a\u523a\u6fc0\u6216\u9577\u671f\u56b4\u91cd\u4f75\u767c\u75c7\uff0c\u4f8b\u5982\u7e7c\u767c\u6027\u764c\u75c7\u548c\u5668\u5b98\u529f\u80fd\u969c\u7919\u3002<\/p>\n

                                \u5e79\u7d30\u80de\u79fb\u690d\u7684\u76f8\u95dc\u98a8\u96aa<\/h3>\n

                                \u9020\u8840\u5e72\u7d30\u80de\u79fb\u690d\u662f\u4e00\u7a2e\u9ad8\u5ea6\u5bc6\u96c6\u7684\u65b9\u6cd5\uff0c\u98a8\u96aa\u76f8\u7576\u9ad8\uff1a<\/p>\n

                                  \n
                                • \u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75be\u75c5 (GVHD)\uff1a<\/strong> \u4e00\u7a2e\u514d\u75ab\u53cd\u61c9\uff0c\u5728\u6350\u8d08\u8005\u79fb\u690d\u5f8c\u6703\u9020\u6210\u5f71\u97ff\u76ae\u819a\u3001\u809d\u81df\u3001\u8178\u9053\u548c\u80ba\u90e8\u7684\u56b4\u91cd\u4f75\u767c\u75c7\u3002<\/li>\n
                                • \u611f\u67d3\u6027\u4f75\u767c\u75c7\uff1a<\/strong> \u56e0\u79fb\u690d\u6240\u9700\u7684\u5f37\u70c8\u514d\u75ab\u6291\u5236\u800c\u7522\u751f\u3002<\/li>\n<\/ul>\n

                                  \u9999\u6e2f\u548c\u4e9e\u6d32\u7279\u6709\u7684\u9650\u5236<\/h3>\n

                                  \u5be6\u969b\u7684\u9650\u5236\u5305\u62ec\u91cf\u8eab\u6253\u9020\u500b\u4eba\u5316\u7642\u6cd5\u6240\u9700\u7684\u5148\u9032\u57fa\u56e0\u6e2c\u8a66\u6709\u9650\u3002\u793e\u6703\u7d93\u6fdf\u969c\u7919\u548c\u5340\u57df\u5dee\u7570\u9650\u5236\u4e86\u53ca\u6642\u7372\u5f97\u53ef\u80fd\u633d\u6551\u751f\u547d\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u4f7f\u9810\u5f8c\u60c5\u6cc1\u548c\u60a3\u8005\u7d50\u679c\u8207\u897f\u65b9\u6a19\u6e96\u76f8\u6bd4\u66f4\u52a0\u60e1\u5316\u3002<\/p>\n

                                  \u7e3d\u7d50<\/h2>\n

                                  \u6301\u7e8c\u7684\u5275\u65b0\u8207\u5168\u7403\u5925\u4f34\u95dc\u4fc2\u63a8\u52d5\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u6cbb\u7642\u7684\u6f14\u9032\uff0c\u7a81\u986f\u51fa\u63d0\u9ad8\u53ef\u53ca\u6027\u8207\u514b\u670d\u76ee\u524d\u6cbb\u7642\u9650\u5236\u7684\u5fc5\u8981\u6027\u3002\u65b0\u8208\u7684\u4ee3\u8b1d\u7642\u6cd5\u548c\u91cf\u8eab\u8a02\u505a\u7684\u500b\u4eba\u5316\u65b9\u6cd5\u63d0\u4f9b\u4e86\u5be6\u8cea\u7684\u5e0c\u671b\uff0c\u4e26\u53ef\u9810\u898b\u60a3\u8005\u7684\u7642\u6548\u6703\u986f\u8457\u6539\u5584\u3002<\/p>","protected":false},"excerpt":{"rendered":"

                                  \u5728 AllCancer \u63a2\u7d22\u6025\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 (AML) \u7684\u75c7\u72c0\u3001\u5206\u671f\u548c\u9769\u547d\u6027\u7684 HK \u4ee3\u8b1d\u7642\u6cd5\u3002<\/p>","protected":false},"author":1,"featured_media":7369,"parent":0,"menu_order":0,"template":"","class_list":["post-7733","cancer_type","type-cancer_type","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/cancer_type\/7733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/cancer_type"}],"about":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/types\/cancer_type"}],"author":[{"embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/media\/7369"}],"wp:attachment":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/media?parent=7733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}